



Imbruvica (for Maryland only)

Prior Authorization Request

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect[®] 1-800-237-2767

wiciant's ID:	NPI#:Physician Office Fax:	
ecialty:	NPI#: Physician Office Fax:	
wsician Office Telephone: quest Initiated For: What is the patient's diagnosis?	Physician Office Fax:	
quest Initiated For: What is the patient's diagnosis?		
What is the patient's diagnosis?	-	
☐ Waldenstrom's Macroglobulinemia/lymphop☐ Chronic lymphocytic leukemia (CLL) or sma☐ Marginal zone lymphoma	Il lymphocytic lymphoma (SLL)	
What is the ICD-10 code?		
Would the prescriber like to request an override ☐ Yes ☐ No If No, skip to diagnosis section	of the step therapy requirement?	
ACTION REQUIRED: Attach documentation	to substantiate the member had a prescription paid for with	ir
nplete the following section based on the patien	t's diagnosis, if applicable.	
tion A: Mantle Cell Lymphoma (MCL)		
Has the patient received at least one prior therap *Note: Examples of therapies for MCL include,	but are not limited to, chemotherapy plus Rituxan, radiation	
tion B: Marginal Zone Lymphoma		
	Yes 🗖 No	
Has the patient previously received an anti-CD2	0-based therapy (e.g., Rituxan)? ☐ Yes ☐ No	
ormation is available for review if requested	by CVS Caremark or the benefit plan sponsor.	
escriber or Authorized Signature	Date (mm/dd/yy)	
:t	□ Chronic lymphocytic leukemia (CLL) or sma □ Marginal zone lymphoma □ Other What is the ICD-10 code? Would the prescriber like to request an override □ Yes □ No If No, skip to diagnosis section Has the member received the medication through ACTION REQUIRED: Attach documentation the past 180 days (i.e. PBM medication history). Is the medication effective in treating the member of the past 180 continue to diagnosis section and plete the following section based on the patient in the patient received at least one prior therapy: *Note: Examples of therapies for MCL include, therapy, Velcade, Revlimid and stem cell transposition B: Marginal Zone Lymphoma Does the patient require systemic therapy? □ Yelset that this information is accurate and transposition is available for review if requested the properties of the properties of the patient requires the patient requires the patient therapy? □ Yelset that this information is accurate and transposition is available for review if requested the properties of the patient requires the patient requested the patient requires the pat	□ Waldenstrom's Macroglobulinemia/lymphoplasmacytic lymphoma □ Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) □ Marginal zone lymphoma □ Other What is the ICD-10 code? Would the prescriber like to request an override of the step therapy requirement? □ Yes □ No If No, skip to diagnosis section Has the member received the medication through a pharmacy or medical benefit within the past 180 days? ACTION REQUIRED: Attach documentation to substantiate the member had a prescription paid for with the past 180 days (i.e. PBM medication history, pharmacy receipt, EOB etc.) □ Yes □ No Is the medication effective in treating the member's condition? □ Yes □ No Continue to diagnosis section and complete this form in its entirety. Inplete the following section based on the patient's diagnosis, if applicable. Ion A: Mantle Cell Lymphoma (MCL) Has the patient received at least one prior therapy for MCL? □ Yes □ No *Note: Examples of therapies for MCL include, but are not limited to, chemotherapy plus Rituxan, radiation therapy, Velcade, Revlimid and stem cell transplantation. Ion B: Marginal Zone Lymphoma Does the patient require systemic therapy? □ Yes □ No Has the patient previously received an anti-CD20-based therapy (e.g., Rituxan)? □ Yes □ No test that this information is accurate and true, and that documentation supporting this formation is available for review if requested by CVS Caremark or the benefit plan sponsor.

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Imbruvica CF - 3/2017.

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. (a) Registered trademark of CareFirst of Maryland, Inc.